Alnylam heralds PhIII APOLLO-B win on way to creating an 'industry leading TTR franchise' - Endpoints News
8/3/2022 12:00:00 AM2 years 9 months ago
by John Carroll
by John Carroll
Alnylam $ALNY has laid claim to a major success in Phase III, with its RNAi drug patisiran hitting the primary endpoint in its APOLLO-B study for ATTR amyloidosis with cardiomyopathy, one of the most important pivotal trials to read out this year. Shares of t…
Alnylam $ALNY has laid claim to a major success in Phase III, with its RNAi drug patisiran hitting the primary endpoint in its APOLLO-B study for ATTR amyloidosis with cardiomyopathy, one of the most… [+798 chars]
full article...